Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
Clinical trial NCT02152956 · TERMINATED
Trial details
- NCT number
- NCT02152956
- Sponsor
- MacroGenics
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-06-09
- Primary completion
- 2022-07-05
- Enrollment
- 244
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.